MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Arcutis Biotherapeutics Inc

Cerrado

SectorSalud

14.66 -5.36

Resumen

Variación precio

24h

Actual

Mínimo

14.46

Máximo

15.71

Métricas clave

By Trading Economics

Ingresos

-14M

-25M

Ventas

-5.5M

66M

Margen de beneficio

-38.059

Empleados

342

EBITDA

-14M

-19M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+37.53% upside

Dividendos

By Dow Jones

Próximas Ganancias

13 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

79M

1.9B

Apertura anterior

20.02

Cierre anterior

14.66

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

169 / 376 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

Arcutis Biotherapeutics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

17 jul 2025, 23:34 UTC

Adquisiciones, fusiones, absorciones

FTC Reopens Consent Orders for Proposed Acquisitions from Exxon Mobil, Chevron

17 jul 2025, 21:14 UTC

Adquisiciones, fusiones, absorciones

Basel Medical Group Puts $1 Billion Bitcoin Purchase on Hold

17 jul 2025, 21:04 UTC

Principales Movimientos del Mercado
Adquisiciones, fusiones, absorciones

Norfolk Southern Shares Rise on WSJ Report of Union Pacific Acquisition Interest

17 jul 2025, 23:43 UTC

Charlas de Mercado

Gold Edges Higher on Possible Position Adjustments -- Market Talk

17 jul 2025, 23:42 UTC

Charlas de Mercado

Nikkei May Rise on Signs of U.S. Econ Strength -- Market Talk

17 jul 2025, 22:47 UTC

Adquisiciones, fusiones, absorciones

FTC: Maintaining Restrictions for Former Pioneer CEO Scott Sheffield Would Damage FTC's Credibility

17 jul 2025, 22:46 UTC

Adquisiciones, fusiones, absorciones

Potential Rail Merger Could Prompt Berkshire Hathaway to Bid for CSX -- Barrons.com

17 jul 2025, 22:46 UTC

Adquisiciones, fusiones, absorciones

FTC Also Says Exxon Order Disregarded Guidelines and Precedent

17 jul 2025, 22:43 UTC

Adquisiciones, fusiones, absorciones

FTC: Maintaining Restrictions on John Hess's Employment Would 'Damage the FTC's Credibility'

17 jul 2025, 22:43 UTC

Adquisiciones, fusiones, absorciones

FTC: Chevron Order Disregarded FTC Merger Guidelines and Decades of Precedent

17 jul 2025, 22:40 UTC

Adquisiciones, fusiones, absorciones

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17 jul 2025, 22:40 UTC

Adquisiciones, fusiones, absorciones

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17 jul 2025, 22:30 UTC

Charlas de Mercado
Ganancias

Netflix Sticks to Its Playbook as Competitive Landscape Changes -- Market Talk

17 jul 2025, 22:20 UTC

Charlas de Mercado
Ganancias

Global Equities Roundup: Market Talk

17 jul 2025, 22:20 UTC

Charlas de Mercado
Ganancias

Netflix Focusing Resources on TV Viewers It Hasn't Yet Captured -- Market Talk

17 jul 2025, 22:04 UTC

Charlas de Mercado
Ganancias

Netflix Redesign Done to Match Current Capabilities -- Market Talk

17 jul 2025, 22:03 UTC

Adquisiciones, fusiones, absorciones

China Threatens to Block Panama Ports Deal Unless Its Shipping Giant Is Part of It -- 2nd Update

17 jul 2025, 21:58 UTC

Charlas de Mercado
Ganancias

Netflix Internal Data Doesn't Indicate Weaker Consumer Sentiment -- Market Talk

17 jul 2025, 21:57 UTC

Ganancias

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17 jul 2025, 21:47 UTC

Ganancias

Netflix Raises Revenue, Margin Forecasts After Strong Second Quarter -- Update

17 jul 2025, 21:45 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

17 jul 2025, 21:45 UTC

Charlas de Mercado

Crypto Bills Welcomed by Venture Capital, Trade Group Says -- Market Talk

17 jul 2025, 21:38 UTC

Adquisiciones, fusiones, absorciones

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- 2nd Update

17 jul 2025, 21:22 UTC

Adquisiciones, fusiones, absorciones

Update: Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17 jul 2025, 21:05 UTC

Ganancias

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17 jul 2025, 21:04 UTC

Adquisiciones, fusiones, absorciones

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- Update

17 jul 2025, 21:02 UTC

Adquisiciones, fusiones, absorciones

Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17 jul 2025, 20:59 UTC

Adquisiciones, fusiones, absorciones

Basel Medical Group Puts $1B Bitcoin Purchase on Hold

17 jul 2025, 20:50 UTC

Charlas de Mercado
Ganancias

Tech, Media & Telecom Roundup: Market Talk

17 jul 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Arcutis Biotherapeutics Inc Esperado

Precio Objetivo

By TipRanks

37.53% repunte

Estimación a 12 meses

Media 21.29 USD  37.53%

Máximo 29 USD

Mínimo 19 USD

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Arcutis Biotherapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

7 ratings

7

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

12.42 / 14.93Soporte y Resistencia

Corto Plazo

Strong Bearish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Bullish Evidence

Sentimiento

By Acuity

169 / 376 Clasificación en Salud

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.